BCL2L1 anticorps (PE)

N° du produit ABIN135024

Cet anticorps anti-BCL2L1 est un anticorps Souris Monoclonal détectant BCL2L1 dans FACS. Adapté pour Humain. Ce Primary Antibody a été cité dans 2+ publications.

Aperçu rapide pour BCL2L1 anticorps (PE) (ABIN135024)

Antigène: BCL2L1 (BCL2-Like 1 (BCL2L1))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp BCL2L1 est conjugé à/à la PE

Application: Flow Cytometry (FACS)

Clone: 7B2-5

Détail du produit anti-BCL2L1 anticorps (PE)

Specificité: Human/Mouse/Rat/Rhesus Bcl-xL

Attributs du produit: Mouse Anti-Bcl-xL-PE

Immunogène: Recombinant human Bcl-xS

Isotype: IgG3

Information d'application

Indications d'application:

• Applications: FC - Quality tested , IHC-PS - Reported in literature , ICC - Reported in literature , WB - Reported in literature , IP - Reported in literature , ELISA - Reported in literature
• Working Dilutions: Flow Cytometry FITC and BIOT conjugates 3 g/106 cells PE conjugate 0.3 g/106 cells For flow cytometry, the suggested use of these reagents is in a final volume of 100 L Immunoblotting Purified (UNLB) antibody 1 g/mL

Volume d'échantillon: 1 mL

Restrictions: For Research Use only

Stockage

Concentration: 0.1 mg/mL

Buffer: 0.1 mg in 1.0 mL of PBS/Sodium azide and a stabilizing agent

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Do not freeze!
Protect conjugated products from light.
Each reagent is stable for the period shown on the bottle label if stored as directed.

Stock: 4 °C

Stockage commentaire: Store at 2-8°C

Références pour anticorps anti-BCL2L1 (PE) (ABIN135024)

Urbanska, Lanitis, Poussin, Lynn, Gavin, Kelderman, Yu, Scholler, Powell: "A universal strategy for adoptive immunotherapy of cancer through use of a novel T cell antigen receptor." dans: Cancer research, (2012) (PubMed).

Gottschalk, Boise, Oltvai, Accavitti, Korsmeyer, Quintáns, Thompson: "The ability of Bcl-x(L) and Bcl-2 to prevent apoptosis can be differentially regulated." dans: Cell death and differentiation, Vol. 3, Issue 1, pp. 113-8, (2006) (PubMed).

Détails sur BCL2L1

Antigène: BCL2L1 (BCL2-Like 1 (BCL2L1))

Autre désignation: Bcl-xL

Sujet: Apoptosis, or programmed cell death, is a well-documented phenomenon in many cellular systems. It plays a key role in tissue and organ development as well as in adult tissues during cell turnover. Apoptosis can be induced by a variety of internal and external stimuli including growth factor deprivation, cytokine treatment, antigen-receptor engagement, cell-cell interactions, irradiation and glucocorticoid treatment. Bcl-2 and one of its homologues, Bcl-xL, protect cells from apoptosis, while other homologues of Bcl-2 such as Bax, Bad and Bak have been shown to enhance apoptosis. Bcl-xL has been shown to block apoptosis which is induced by a variety of stimuli and, under certain conditions, offers greater protection against apoptosis than Bcl-2. In contrast, Bad and Bax inhibit the protective functions of Bcl-xL and Bcl-2, respectively. Although heterodimerization between Bcl-xL/Bad and Bcl-2/Bax was originally thought to be essential for the differential anti-apoptotic activity of Bcl-xL and Bcl-2, other results suggest that the formation of heterodimers may not be necessary for this death-repressing activity.

Pathways: Apoptose, Negative Regulation of intrinsic apoptotic Signaling